DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Aripiprazole Oral Acceptability Trial

Information source: Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Schizophrenia

Intervention: Aripiprazole (Drug); Aripiprazole (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Otsuka Pharmaceutical Development & Commercialization, Inc.

Official(s) and/or principal investigator(s):
Bristol-Myers Squibb, Study Director, Affiliation: Bristol-Myers Squibb

Summary

The purpose of this trial is to study liquid aripiprazole in patients with stable schizophrenia.

Clinical Details

Official title: Aripiprazole Oral Acceptability Trial

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: acceptability

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Stable patients currently receiving aripiprazole or other antipsychotic medications.

Locations and Contacts

Local Institution, Anaheim, California, United States

Local Institution, National City, California, United States

Local Institution, North Miami Beach, Florida, United States

Local Institution, Overland Park, Kansas, United States

Local Institution, Staten Island, New York, United States

Local Institution, Oklahoma City, Oklahoma, United States

Local Institution, Falls Church, Virginia, United States

Additional Information

BMS Clinical Trials Disclosure

For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm

Starting date: March 2004
Last updated: November 7, 2013

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017